Matchmaking And Integration In The New World Of Diagnostics M&A

Nontraditional buyers, including Big Pharmas, life science tool companies, diversified conglomerates, and even food companies, are snapping up molecular diagnostics assets with increasing frequency, applying a variety of models to enhance their businesses.

Until recently, in vitro diagnostics were priced nearly at commodity levels and were relegated to the relative backwaters of the life science universe. That’s changed, however, with the advent of molecular diagnostics tests that deliver more meaningful clinical value at correspondingly higher price points. As the value proposition has improved, the assemblage of companies vying for promising molecular diagnostics assets has changed as well. Seeking to capitalize on the potential of molecular diagnostics, nontraditional buyers have begun to enter into the sector, competing with traditional clinical diagnostics and diversified lab players such as Beckman Coulter Inc. (now a division of Danaher Corp.[See Deal]), Quest Diagnostics Inc., and Laboratory Corp. of America Holdings. Deals by nontraditional buyers, which we define here as companies deriving less than 50% of revenue from diagnostics, have grown from 33% of molecular diagnostics M&A deals consummated between 2007-2008 to 63% of molecular diagnostics M&A activity between 2011-2012. (See Exhibit 1.) Due to their outsized role in the evolving molecular diagnostics M&A landscape, understanding the unique dynamics of these acquisitions as well as the form and structure of post-acquisition integration has consequences for all molecular diagnostics players as they predict the future makeup of the market and their position within it.

Exhibit 1

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deal-Making

Deals In Depth: June 2025

 
• By 

Five $1bn+ alliances were penned in June, and four exceeded $2bn.

Deals Shaping The Industry, June 2025

 
• By 

An interactive look at pharma, medtech and diagnostics deals made during June 2025. Data courtesy of Biomedtracker.

Behind The Buyout: Dispatches From The Dealmaking Table

 
• By 

In a challenging funding environment for biopharma, strategic dealmaking has become a critical growth engine. In Vivo explores what it truly takes to navigate high-stakes acquisitions and partnerships, drawing on insights from seasoned industry leaders.

Deals Shaping The Industry, May 2025

 
• By 

An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.

More from In Vivo

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

 
• By 

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.

Execs On The Move: June 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

AI In Biologics Discovery: The Expensive Bet On Unproven Promise

 
• By 

Despite limited evidence of commercial impact, pharmaceutical companies are making massive strategic investments in AI biologics platforms. The question isn't whether the technology shows promise; it's whether that promise can translate to measurable business results.